---
title: "Psych News Alert: Lurasidone Gains New Indication for Bipolar Depression"
description: The U.S. Food and Drug Administration (FDA) has approved  new indications for the atypical antipsychotic drug lurasidone (Latuda; Sunovion) ...
image: https://alert.psychnews.org/hubfs/Imported_Blog_Media/DepressSilhouette_127174199-Jun-24-2025-04-40-11-6255-PM.jpg
---

 7/3/13 12:00 AM

# Lurasidone Gains New Indication for Bipolar Depression

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [ Psychiatric News Alert ](https://alert.psychnews.org/author/psychiatric-news-alert)

Share: [facebook-f icon ](http://www.facebook.com/share.php?u=https://alert.psychnews.org/2013/07/lurasidone-gains-new-indication-for.html) [linkedin-in icon ](http://www.linkedin.com/shareArticle?mini=true&url=https://alert.psychnews.org/2013/07/lurasidone-gains-new-indication-for.html) [Twitter icon ](https://twitter.com/intent/tweet?url=https://alert.psychnews.org/2013/07/lurasidone-gains-new-indication-for.html) [pinterest-p icon ](http://pinterest.com/pin/create/link/?url=https://alert.psychnews.org/2013/07/lurasidone-gains-new-indication-for.html) [envelope icon ](mailto:?body=https://alert.psychnews.org/2013/07/lurasidone-gains-new-indication-for.html)

| [![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/DepressSilhouette_127174199-Jun-24-2025-04-40-12-6161-PM.jpg?width=132&name=DepressSilhouette_127174199-Jun-24-2025-04-40-12-6161-PM.jpg)](https://alert.psychnews.org/hubfs/Imported_Blog_Media/DepressSilhouette_127174199-Jun-24-2025-04-40-13-4670-PM.jpg) |  |
| --- | --- |

The U.S. Food and Drug Administration (FDA) has [approved](http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/200603Orig1s010,s011ltr.pdf) new indications for the atypical antipsychotic drug lurasidone (Latuda; Sunovion) in treatment of patients with depressive episodes associated with bipolar I disorder. The approval covers use alone and as adjunctive therapy with lithium or valproate.

“Its utility as monotherapy and adjunctive therapy places the drug in a select position in an area with few other medication choices,” said Roger McIntyre, M.D., a professor of psychiatry and pharmacology at the University of Toronto, in an interview. Lurasidone was already approved for use in patients with schizophrenia.

With the new indications, the drug appeared to cause fewer metabolic problems or weight gain than other drugs in its class, said McIntyre, who formerly consulted with Sunovion’s Canadian affiliate, but does not do so now.

In two clinical trials submitted to the FDA, lurasidone was tested over its complete dosing range of 20mg to 120 mg day, and average weight gain was 0.3 kg with monotherapy and 0.1 kg with adjunctive use, said psychiatrist Antony Loebel, M.D., chief medical officer at Sunovion. Trial results were presented as posters at APA's 2012 annual meeting and have been submitted for publication.

The new indication should help fill the unmet need for more treatment options for clinicians and their patients with bipolar depression, said Loebel.

For more in *Psychiatric News* about medications used to treat bipolar depression, click [here](http://psychnews.psychiatryonline.org/newsarticle.aspx?articleid=1702075).

(Image: Bartek Zyczynski/Shutterstock.com)

[psychiatry](https://alert.psychnews.org/tag/psychiatry), [antipsychotic medications](https://alert.psychnews.org/tag/antipsychotic-medications), [Latuda](https://alert.psychnews.org/tag/latuda), [bipolar depression](https://alert.psychnews.org/tag/bipolar-depression), [lurasidone](https://alert.psychnews.org/tag/lurasidone), [Loebel](https://alert.psychnews.org/tag/loebel), [Sunovion](https://alert.psychnews.org/tag/sunovion), [McIntyre](https://alert.psychnews.org/tag/mcintyre)

## Related posts

[![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/FDA_NewLogo-Jun-24-2025-10-34-00-3283-PM.jpg?height=200&name=FDA_NewLogo-Jun-24-2025-10-34-00-3283-PM.jpg) ](https://alert.psychnews.org/2018/03/fda-approves-latuda-for-treatment-of.html)

[youth](https://alert.psychnews.org/tag/youth), [Latuda](https://alert.psychnews.org/tag/latuda), [expanded indication](https://alert.psychnews.org/tag/expanded-indication), [Sunovion Pharmaceuticals](https://alert.psychnews.org/tag/sunovion-pharmaceuticals), [Robert Findling](https://alert.psychnews.org/tag/robert-findling), [FDA approval](https://alert.psychnews.org/tag/fda-approval), [bipolar depression](https://alert.psychnews.org/tag/bipolar-depression), [lurasidone](https://alert.psychnews.org/tag/lurasidone), [FDA](https://alert.psychnews.org/tag/fda)

## [FDA Approves Latuda for Treatment of Youth With Bipolar Depression](https://alert.psychnews.org/2018/03/fda-approves-latuda-for-treatment-of.html)

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 

 3/8/18 12:00 AM

The Food and Drug Administration (FDA) has approved Latuda (lurasidone HCl) for the treatment of...

[ Read more ](https://alert.psychnews.org/2018/03/fda-approves-latuda-for-treatment-of.html)

[![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/FDA_NewLogo-Jun-24-2025-09-48-32-0835-PM.jpg?height=200&name=FDA_NewLogo-Jun-24-2025-09-48-32-0835-PM.jpg) ](https://alert.psychnews.org/2019/05/vraylar-now-approved-for-full-spectrum.html)

[bipolar disorder](https://alert.psychnews.org/tag/bipolar-disorder), [bipolar depression](https://alert.psychnews.org/tag/bipolar-depression), [Allergan](https://alert.psychnews.org/tag/allergan), [cariprazine](https://alert.psychnews.org/tag/cariprazine), [Vraylar](https://alert.psychnews.org/tag/vraylar), [Stephen Stahl](https://alert.psychnews.org/tag/stephen-stahl), [depressive episode](https://alert.psychnews.org/tag/depressive-episode)

## [Vraylar Now Approved for Full Spectrum of Bipolar I Disorder Symptoms](https://alert.psychnews.org/2019/05/vraylar-now-approved-for-full-spectrum.html)

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 

 5/29/19 12:00 AM

Yesterday the Food and Drug Administration (FDA) approved Vraylar (cariprazine) for the treatment...

[ Read more ](https://alert.psychnews.org/2019/05/vraylar-now-approved-for-full-spectrum.html)

[![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/AVvXsEjRZGQ1JY3RXhddFsURsOWgk49SHn2wO9g1dL0lecnXD-seRDWc5cd7tOkDx-MwaNoWxtXKOE60Q8mrU_xXZRYN_2x70IX4ho4edh1QuZtiFFbm-QhQJIYaH2SpdyXWL35NWP2teCjaP4MJY-Jun-24-2025-06-07-28-3063-PM.jpg?height=200&name=AVvXsEjRZGQ1JY3RXhddFsURsOWgk49SHn2wO9g1dL0lecnXD-seRDWc5cd7tOkDx-MwaNoWxtXKOE60Q8mrU_xXZRYN_2x70IX4ho4edh1QuZtiFFbm-QhQJIYaH2SpdyXWL35NWP2teCjaP4MJY-Jun-24-2025-06-07-28-3063-PM.jpg) ](https://alert.psychnews.org/2021/12/caplyta-approved-for-bipolar-depression.html)

[schizophrenia](https://alert.psychnews.org/tag/schizophrenia), [bipolar disorder](https://alert.psychnews.org/tag/bipolar-disorder), [antipsychotic](https://alert.psychnews.org/tag/antipsychotic), [bipolar depression](https://alert.psychnews.org/tag/bipolar-depression), [lumateperone](https://alert.psychnews.org/tag/lumateperone), [FDA](https://alert.psychnews.org/tag/fda), [Food and Drug Administration](https://alert.psychnews.org/tag/food-and-drug-administration), [drug development](https://alert.psychnews.org/tag/drug-development), [monotherapy](https://alert.psychnews.org/tag/monotherapy), [Caplyta](https://alert.psychnews.org/tag/caplyta)

## [Caplyta Approved for Bipolar Depression in Adults](https://alert.psychnews.org/2021/12/caplyta-approved-for-bipolar-depression.html)

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 

 12/20/21 12:00 AM

[ Read more ](https://alert.psychnews.org/2021/12/caplyta-approved-for-bipolar-depression.html)

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Psychiatric News Alert",
    "url" : "https://alert.psychnews.org/author/psychiatric-news-alert"
  },
  "dateModified" : "2025-06-24T16:43:50.137Z",
  "datePublished" : "2013-07-03T04:00:00.000Z",
  "headline" : "Psych News Alert: Lurasidone Gains New Indication for Bipolar Depression",
  "image" : [ "https://alert.psychnews.org/hubfs/Imported_Blog_Media/DepressSilhouette_127174199-Jun-24-2025-04-40-11-6255-PM.jpg" ],
  "mainEntityOfPage" : {
    "@id" : "https://alert.psychnews.org/2013/07/lurasidone-gains-new-indication-for.html",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://alert.psychnews.org/hubfs/PN-Blue-Box.jpg"
    }
  }
}
```